Clinical trials: cTACE
Hypervascular Tumors
Instylla HES Hypervascular Tumor Pivotal Study
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional…
- Trial name
- NCT04523350
- Testing
- Instylla HES, TAE or cTACE
- Where
- 15 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Instylla, Inc.
Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
- Trial name
- NCT04635527
- Testing
- IBI318, cTACE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Oncology
Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up
This study is conducted within the frame of the Post-Market Surveillance (PMS) activities, as described in the Post Market Clinical Follow-up (PMCF) plan of Vectorio®.
- Trial name
- NCT05316077
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Guerbet
HCC
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
This study is A Randomized, Active-Controlled, Open-Label National Multicenter Phase 2 Registration Clinical Study of Yttrium [90Y] Microsphere Injection in Combination with Camrelizumab and/or Apatinib and Yttrium [90Y]…
- Trial name
- NCT07334483
- Testing
- Yttrium [90Y] Microsphere Injection, Conventional transcatheter arterial chemoembolization, Camrelizumab
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Unresectable Hepatocellular Carcinoma
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
- Trial name
- CHEERS (NCT06900543)
- Testing
- NRT6003 Injection, cTACE
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
HCC
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06844357
- Testing
- tirapazamine, Transarterial Embolization (TAE), TACE
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Inoperable Hepatocellular Carcinoma
MANDARIN (S6371)
To evaluate the efficacy and safety of TheraSphereTM yttrium [90Y] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.
- Trial name
- NCT05016245
- Testing
- TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Boston Scientific Corporation